☆ 4.4 Letter

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

ACTA ONCOLOGICA (2021)

Get Full Text
Add to Collection

Journal

ACTA ONCOLOGICA
Volume 60, Issue 4, Pages 549-553

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/0284186X.2020.1871067

Keywords

-

Categories

Oncology

Funding

  1. Bayer
  2. ESMO

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.